Solute Carrier Family 6 (Neurotransmitter Transporter, Noradrenalin), Member 2 (SLC6A2) ELISA Kits

Human Solute Carrier Family 6 (Neurotransmitter Transporter, Noradrenalin), Member 2 (SLC6A2) interaction partners

1. Study finds that ketamine influences the locus coeruleus norepinephrine network, with a dependency on norepinephrine transporter genotype.

2. Our case-control study and meta-analysis suggest that the NET gene G1287A polymorphism may not be involved in the etiology of schizophrenia in the Chinese Han population

3. genetic association/pharmacogenetic studies in population in Switzerland: Data from controlled studies suggest that SNPs in SLC6A2 (rs1861647, rs2242446, rs36029) weakly moderate acute cardiovascular response to MDMA (methylenedioxymethamphetamine, "ecstasy") and may play minor role in adverse cardiovascular events when MDMA is used recreationally.

4. Our study indicates that DNA methylation levels of nine CpG sites in NET gene promoter region are not associated with depression and hypertension.

5. case-control study by genotyping 7 SNPs of SLC6A2, SLC6A3 and DRD2 in 1034 schizophrenia patients and 1034 controls. No significant difference in the allelic or genotypic frequency was detected between cases and controls

6. nine ADHD candidate single nucleotide polymorphisms (SNPs) in seven genes were tested for association with PD in 5333 cases and 12,019 healthy controls. No significant association was observed.

7. T allele of the SNP rs7194256 in the 3'UTR of the NET gene is more prevalent in diseases where NET impairment is evident, including essential hypertension, depression, panic disorder and postural orthostatic tachycardia syndrome; mechanism involved may include the creation of a binding site for the miRNA miR-19-3p, which is, at least in part, regulated by circulating norepinephrine concentrations

8. Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease

9. NET rs2242446/T-182C may serve as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major depression. These findings may help to optimize antidepressant outcomes in older adults.

10. These results suggest that NET polymorphism may affect the SNRI response in Korean panic disorder patients.

11. Imaging genetic study showed significant differences in NET nondisplaceable binding potential in patients with attention deficit hyperactivity disorder compared to healthy controls, depending on their genotype

12. NET undergoes extensive constitutive internalization and internalized NET mainly is sorted to Rab11-positive recycling endosomes.

13. In Major Depressive Disorder patients there seems to be a relationship between the volume of the dorsolateral prefrontal cortex and polymorphism of the SLC6A2 G1287A gene.

14. This corticotropin releasing factor-induced regulation on norepinephrine transporter expression and function may play a role in development of stress-related depression and anxiety

15. Study identified the haplotype rs36011 (T)/rs1566652 (G) as a novel genetic marker involved in both attention-deficit/hyperactivity disorder disease susceptibility and visual memory

16. a NET 182C and 5-HTTLPR polymorphism interaction is associated with susceptibility to treatment resistant depression and ECT treatment response in antidepressant resistant depression patients

17. NET gene variants are not involved in the etiology of recurrent major depressive disorder in Chinese Han population.

18. Different combinations of T-182C and the G1287A polymorphisms of NET gene might increase morbidity risk of major depression subpopulations

19. A Cox regression analysis for remission incidence during the 8-week treatment course significantly depends on SLC6A2 variants (rs28386840, rs40434, and rs187714)from major depression after venlafaxine treatment.

20. The response to venlafaxine was assessed after 4 weeks of treatment and correlated to serum concentration and functional variants in genes encoding SLC6A2 and SLC6A4

Mouse (Murine) Solute Carrier Family 6 (Neurotransmitter Transporter, Noradrenalin), Member 2 (SLC6A2) interaction partners

1. Differences in gene expression in the mouse frontal cortex with life-long norepinephrine transporter knock-out were studied using a whole-genome microarray approach

2. inhibition of p38 MAPK or the manipulation of NET-Thr(30) motif/phosphorylation via a TAT peptide strategy prevents cocaine-induced NET up-regulation, locomotor sensitization, and conditioned place preference

3. this is the first report which suggests the beneficial effect of modulation of TRPV1 receptors and NET in Chronic cerebral hypoperfusion vascular dementia

4. daily sympathetic activation induced by mild chronic stress was unable to induce bone loss, unless NET activity was blocked.

5. NET dysfunction is sufficient to produce a postural orthostatic tachycardia syndrome phenotype.

6. Norepinephrine transporter has a greater role in determining baseline analgesia and other analgesic effects in mice than serotonin transporter.

7. NET expression is essential for development and/or survival of some (5-HT- and calretinin-expressing), but not all (nNOS-expressing), of these neurons.

8. propose that amplified norepinephrine transporter function in rictor KO mice enhances accumulation of both norepinephrine and dopamine within the noradrenergic neuron

9. Report a protocol to monitor NET transport rate at the level of the single nerve terminal varicosity using a fluorescent substrate.

10. We identified that gene expression in neuronal cortical cells involves increased histone hyperacetylation on the Slc6a2 promoter, which is commensurate with the recruitment of SP1 and RNA Polymerase II and is inversely correlated with H3K9 trimethylation.

11. Data demonstrate that estrogen exerts significant modulatory effects on olfactory bulb function through modulation of tyrosine hydroxylase, dopamine transporter and norepinephrine transporter expression.

12. NET function may be a physiologically relevant regulatory element in embryonic development.

13. NET deficiency increases extraneuronal levels of NE, dopamine, & epinephrine. The impact of this hyperadrenergic state is greatest in the periphery & is manifested by high blood pressure & excessive tachycardia with wakefulness & physical activity.

14. this is the first report to suggest that the norepinephrine transporter gene is one of many possible genetic factors influencing ethanol sensitivity in ILS, ISS, and LXS RI mouse strains

15. Knockout mice showed enhanced binding of the selective alpha(2)drenergic antagonist [(3)H]RX821002 in several brain regions

16. The effects of DAT KO in animal models of depression are larger than those produced by NET or SERT KO, and unlikely to be simply the result of the confounding effects of locomotor hyperactivity.

17. a novel triple mutation that retains close to wild-type transport function but displays a 37-fold decrease in cocaine sensitivity and 24-fold decrease in desipramine sensitivity.

18. Data further suggest deregulation of signaling pathways in the development and/or function of the NET-deficient peripheral, central and enteric nervous systems.

19. conditioned locomotion was not observed in DAT KO mice, and was reduced in SERT KO and NET KO mice.

20. resistance of the NET KO mice to the stress-induced depression-associated behaviors and biochemical changes highlight the importance of noradrenergic pathways in the maintenance of mood